Table 2 Summary of changes in best‐corrected visual acuity.
| Mean value for each dosage group | 4 mg (n = 23) | SD | 8 mg (n = 20) | SD | p Value |
|---|---|---|---|---|---|
| Baseline BCVA (ETDRS logMar units) (approx Snellen equivalent) | 0.81 (20/130) | 0.26 | 0.79 (20/125) | 0.3 | 0.81 |
| BCVA at 2 weeks | 0.71 | 0.26 | 0.65 | 0.31 | 0.49 |
| BCVA at 4 weeks | 0.66 | 0.28 | 0.62 | 0.26 | 0.57 |
| BCVA at 9 weeks | 0.70 | 0.28 | 0.61 | 0.27 | 0.26 |
| BCVA at 17 weeks | 0.69 | 0.26 | 0.60 | 0.26 | 0.23 |
| BCVA at 26 weeks (Approx Snellen equivalent) | 0.75 (20/110) | 0.29 | 0.59 (20/80) | 0.27 | 0.078 |
| BCVA improvement at 2 weeks (number of ETDRS letters) | 4.9 | 8.7 | 6.8 | 9.4 | 0.5 |
| BCVA improvement at 4 weeks | 7.3* | 10.3 | 8.7 | 10.5 | 0.67 |
| BCVA improvement at 9 weeks | 5.4 | 8.3 | 9.2 | 10.5 | 0.19 |
| BCVA improvement at 17 weeks | 6.0 | 9.3 | 9.7 | 10.4 | 0.22 |
| BCVA improvement at 26 weeks | 3.1 | 10 | 9.9* | 11.7 | 0.047 |
| Number (proportion) of eyes with BCVA improvement of ⩾15 ETDRS letters at 6 months | 3 (13%) | 6 (30%) | 0.26 | ||
| Number (proportion) of eyes with BCVA deterioration of ⩾15 ETDRS letters at 6 months | 2 (8%) | 1 (5%) | 1.0 | ||
BCVA, best‐corrected visual acuity; ETDRS, Early Treatment of Diabetic Retinopathy Study; logMar, logarithm of minimum angle of reolution.
*Best BCVA improvement within group.